Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +16.10%
#2 Fake World Assets Fake World Assets +11.89%
#3 OriginTrail OriginTrail +8.84%
#4 B3 (Base) B3 (Base) +7.77%
#5 Pons Pons +5.38%
#6 Storj Storj +5.13%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +4.30%
#8 Audiera Audiera +3.81%
#9 Strategy PP Variable xStock Strategy PP Variable xStock +3.03%
#10 Geodnet Geodnet +2.92%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Pozycja w akcjach #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Cena akcji
$1.54
Ostatnia synchronizacja: 2024-04-08
Kapitalizacja rynkowa
$119.21M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel NGM Biopharmaceuticals, Inc. (NGM)

Kategoria

Healthcare
Historia ceny akcji dla NGM Biopharmaceuticals, Inc. (NGM)
Najwyższa cena zamknięcia: $1.55 dnia 2024-04-01

Najniższa cena zamknięcia: $15.78 dnia 2019-04-01
Historia cen akcji firmy NGM Biopharmaceuticals, Inc. od 2019 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2024 86.99%
2023 -84.01%
2022 -71.29%
2021 -34.64%
2020 51.84%
2019 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $119.69 -14.89%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH